0001209191-18-050101.txt : 20180907 0001209191-18-050101.hdr.sgml : 20180907 20180907165823 ACCESSION NUMBER: 0001209191-18-050101 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20180829 FILED AS OF DATE: 20180907 DATE AS OF CHANGE: 20180907 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McLoughlin Dennis CENTRAL INDEX KEY: 0001752004 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35060 FILM NUMBER: 181060683 MAIL ADDRESS: STREET 1: C/O PACIRA PHARMACEUTICALS, INC. STREET 2: 5 SYLVAN WAY, SUITE 300 CITY: PARSIPPANY STATE: NJ ZIP: 07054 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Pacira Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001396814 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 510619477 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5 SYLVAN WAY STREET 2: SUITE 300 CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: 973-254-3560 MAIL ADDRESS: STREET 1: 5 SYLVAN WAY STREET 2: SUITE 300 CITY: PARSIPPANY STATE: NJ ZIP: 07054 FORMER COMPANY: FORMER CONFORMED NAME: PACIRA INC DATE OF NAME CHANGE: 20080318 FORMER COMPANY: FORMER CONFORMED NAME: Blue Acquisition Corp DATE OF NAME CHANGE: 20070418 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2018-08-29 0 0001396814 Pacira Pharmaceuticals, Inc. PCRX 0001752004 McLoughlin Dennis C/O PACIRA PHARMACEUTICALS, INC. 5 SYLVAN WAY, SUITE 300 PARSIPPANY NJ 07054 0 1 0 0 Chief Commercial Officer Common Stock 14833 D Stock Option (Right to Buy) 33.10 2028-07-03 Common Stock 20000 D Stock Option (Right to Buy) 38.35 2028-06-13 Common Stock 47250 D Stock Option (Right to Buy) 44.20 2027-06-14 Common Stock 6000 D Stock Option (Right to Buy) 44.10 2027-06-02 Common Stock 10000 D Stock Option (Right to Buy) 41.90 2027-02-02 Common Stock 3000 D Stock Option (Right to Buy) 32.35 2026-12-07 Common Stock 6000 D Stock Option (Right to Buy) 40.34 2026-06-15 Common Stock 2400 D Stock Option (Right to Buy) 79.43 2025-06-03 Common Stock 3500 D Stock Option (Right to Buy) 56.32 2024-01-03 Common Stock 10623 D Includes 11,162 unvested restricted stock units. The unvested restricted stock units vest as follows: (i) 437 restricted stock units that vest on June 3, 2019, (ii) 600 restricted stock units that vest in two equal annual installments on June 3, 2019 and June 3, 2020, (iii) 2,250 restricted stock units that vest in three equal annual installments on June 3, 2019, June 3, 2020, June 3, 2021, and (iv) 7,875 restricted stock units that vest in four equal annual installments on June 3, 2019, June 3, 2020, June 3, 2021 and June 3, 2022, in each case provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. The stock options are fully vested. /s/ Kristen Williams, Attorney-in-Fact 2018-09-07 EX-24 2 attachment1.htm EX-24 DOCUMENT

POWER OF ATTORNEY

I, Dennis McLoughlin, hereby authorize and designate each of Charles A.
Reinhart, III, Kristen Williams and Ned Prusse, signing singly, as
my true and lawful attorney-in-fact to:

	(1)	execute for and on my behalf, in my capacity as an officer
and/or director of Pacira Pharmaceuticals, Inc. and its affiliates (the
"Company"), the Form ID and Forms 3, 4 and 5 in accordance with Section
16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange
Act") and the rules and regulations promulgated thereunder;

	(2)	do and perform any and all acts for and on my behalf which
may be necessary or desirable to complete and execute any such Form ID or
Form 3, 4 or 5 and timely file such form with the Securities and Exchange
Commission, any stock exchange or similar authority; and

	(3)	take any other action of any type whatsoever in connection
with the foregoing which, in the opinion of such attorney-in-fact, may be
to my benefit, in my best interest, or legally required of me, it being
understood that the statements executed by such attorney-in-fact on my
behalf pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in
such attorney-in-fact's discretion.

	I hereby further grant to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of the
rights and powers herein granted, as fully to all intents and purposes as
I might or could do if personally present, with full power of substitutes
or revocation, hereby ratifying and confirming all that such attorney-in
fact, or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this Power of Attorney and
the rights and powers herein granted.  I hereby acknowledge that the
foregoing attorneys-in-fact, in serving in such capacity at my request,
are not assuming, nor is the Company assuming, any of my responsibilities
to comply with Section 16 of the Exchange Act.

	This Power of Attorney shall remain in full force and effect until
I am no longer required to file the Form ID or Forms 3, 4 and 5 with
respect to my holdings of and transactions in securities issued by the
Company, unless earlier revoked by me in a signed writing delivered to
the foregoing attorneys-in-fact.

	IN WITNESS WHEREOF, I have caused this Power of Attorney to be duly
executed as of this 30th day of August, 2018.


							/s/ Dennis McLoughlin
							Dennis McLoughlin